[Interleukin-21, new adjuvant for cancer therapy?].
Iannello
Alexandre
A
Ahmad
Ali
A
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004354:Drug Screening Assays, Antitumor; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects / Q000502:physiology; D007378:Interleukins / Q000008:administration & dosage / Q000502:physiology / Q000627:therapeutic use*; D016393:Lymphoma, B-Cell / Q000188:drug therapy; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy; D008545:Melanoma / Q000188:drug therapy; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy*; D000098546:Interleukin-21
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D007378:Interleukins; D000098546:Interleukin-21